New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 7, 2014
10:51 EDTFDO, COV, IGT, BIIB, SHPG, TIBX, NVDA, CZR, OREX, ESIOptions with increasing implied volatility
Options with increasing implied volatility: ESI OREX CZR NVDA TIBX SHPG BIIB IGT COV FDO
News For ESI;OREX;CZR;NVDA;TIBX;SHPG;BIIB;IGT;COV;FDO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
March 20, 2015
10:51 EDTBIIBBiogen hits fresh 52-week high, retraces, levels to watch
Subscribe for More Information
10:00 EDTSHPGOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:41 EDTSHPGBernstein global specialty pharma analyst holds analyst/industry conference call
Subscribe for More Information
09:24 EDTBIIBOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Ctrip.com (CTRP), up 20.1%... Rally Software (RALY), up 17.3%... Nike (NKE), up 5.2%... Darden Restaurants (DRI), up 4.3%... Cheetah Mobile (CMCM), up 3.6%. ALSO HIGHER: Prothena (PRTA), up 40.2% after reporting positive results from Phase 1 study of PRX002... Viggle (VGGL), up 26.9% after confirming receipt of offer from chairman and CEO Robert Sillerman... Intercept Pharmaceuticals (ICPT), up 8.5% after announcing new data analyses from FLINT trial... Biogen Idec (BIIB), up 9.7% after presenting positive interim results from study of aducanumab... Pier 1 Imports (PIR), up 5.2% after being upgraded to Outperform from Perform at Oppenheimer... JinkoSolar (JKS), up 2.8% after announcing that it will supply 75 MWdc of its PV solar modules to Red Horse 2 project and following a strategic collaboration agreement with DuPont (DD). DuPont is up just under 1%. DOWN AFTER EARNINGS: AK Steel (AKS), down 6.8%... Youku Tudou (YOKU), down 4.9%... Tiffany (TIF), down 3.3%. ALSO LOWER: Macerich (MAC), down 7.7% after Simon makes $95.50 per share "best and final" offer.
09:01 EDTBIIBEli Lilly up 2% to $75.75 in pre-market trading
Subscribe for More Information
08:42 EDTBIIBBiogen price target raised to $500 from $421 at Piper Jaffray
Subscribe for More Information
08:12 EDTSHPGShire upgraded to Outperform from Market Perform at Bernstein
Bernstein upgraded Shire as the firm thinks that the stock's risk/reward ratio is positive following several new developments. Among these developments are the firm's belief that the company's orphan drug strategy looks increasingly strong, while the risks to the company's Vyvanse and mesalamines drugs look to have moderated and the company has several near-term, 2015 catalysts. Target $295.
07:45 EDTBIIBBiogen price target raised to $500 from $435 at Barclays
Barclays raised Biogen's price target to $500 following impressive full results from the Phase 1b study of BIIB037 in Alzheimer's disease. The data provided evidence of statistically significant benefits and justify the decision to advance into pivotal studies. Shares are Overweight rated.
06:47 EDTCZRCreditors dispute 'inside deals' surrounding Caesars loyalty program, WSJ says
Caesars Entertainment's (CZR) customer loyalty program has been valued at $1B by creditors, who alleged in lawsuits surrounding its January bankruptcy that the Caesars parent company and majority stake holder Apollo (APO) made several improper deals designed to keep the loyalty unit inaccessible to creditors, reports the Wall Street Journal. Fitch Ratings analyst Alex Bumazhny now calls a swift bankruptcy process "increasingly unlikely," while the presiding judge gave additional scope last week to investigate the disputed deals. Reference Link
06:06 EDTBIIBStocks with implied volatility above IV index mean; CTRP BIIB
Subscribe for More Information
05:37 EDTBIIBBiogen presents positive interim results from study of aducanumab
Subscribe for More Information
March 19, 2015
13:07 EDTBIIBBiogen volatility elevated into Alzheimer's data
Subscribe for More Information
07:12 EDTBIIBBiogen price target raised to $500 from $400 at Credit Suisse
Subscribe for More Information
March 18, 2015
12:48 EDTBIIBFly Watch: Biogen predicted to report strong Alzheimer's data this Friday
Subscribe for More Information
08:03 EDTSHPGTherapeuticsMD names Angus Russell, J. Martin Carroll as directors
TherapeuticsMD (TXMD) announced the appointment of two biopharmaceutical senior executives, Angus C. Russell and J. Martin Carroll, as independent members of its board of directors, and that Randall S. Stanicky has stepped down from the board of directors. Angus C. Russell served as CEO of Shire PLC (SHPG) from June 2008 until April 2013. J. Martin Carroll served as president and CEO of Boehringer Ingelheim Corp. U.S. from 2003 until 2011.
07:34 EDTBIIBBiogen should report strong Alzheimer's data, says RBC Capital
Subscribe for More Information
07:33 EDTESIITT Educational receives notice from NYSE on late filing status
ITT Educational Services announced that it did not file its Annual Report on Form 10-K for the fiscal year ended December 31, 2014 on or before the due date of March 16, 2015. The company has received a notice from the NYSE that the company is subject to the NYSE's procedures under its timely filing criteria as a result of the company's failure to file the 2014 Form 10-K by the due date. Under NYSE rules, the company has six months from March 16, 2015 to file the 2014 Form 10-K. Until the company files the 2014 Form 10-K and all other periodic reports with subsequent due dates, its common stock will remain listed on the NYSE under the symbol "ESI," with a "LF" indicator to signify late filing status. The company can regain compliance with the NYSE listing standards during the six-month period once it files the 2014 Form 10-K with the SEC, but only if it has also filed all other periodic reports with subsequent due dates. The company is still evaluating the full impact of the consolidation of the 2009 Entity on these matters, and therefore cannot provide any assurance that the consolidation of 2009 Entity will not have a material negative impact on these matters, which could result in a material adverse effect on the company's results of operations, financial condition and/or cash flows. Further, the company did anticipate that it may be in noncompliance with certain covenants under its financing agreement.
07:22 EDTSHPGShire looking for 'transformational' deal, Betaville blog says
Subscribe for More Information
07:15 EDTCZRCaesar's says disputes raise 'substantial doubt' about 'going concern' status
Caesar's stated in a regulatory filing after the close Monday that the company is subject to currently pending or threatened litigation and demands for payment by certain creditors asserting CEC is obligated under the former parent guarantee of certain CEOC defaulted debt. The litigation pending against CEOC, and in certain cases against CEC and its other subsidiaries, have been stayed due to the Chapter 11 bankruptcy process, however, certain litigation and the demands against CEC are continuing outside of the Chapter 11 bankruptcy process. "We believe that the Litigation claims and Demands against CEC are without merit and intend to defend ourselves vigorously. At the present time, we believe it is not probable that a material loss will result from the outcome of these matters," Caesar's stated. The noteholder disputes are in their very preliminary stages and discovery has begun on the unsecured note lawsuits, the company noted. "Should these matters ultimately be resolved through litigation outside of the CEOC Financial Restructuring, and were a court to find in favor of the claimants in any of these Noteholder Disputes, such determination could have a material adverse effect on our business, financial condition, results of operations, and cash flows. Accordingly, we have concluded that the material uncertainty related to certain of the Litigation proceeding against CEC raises substantial doubt about the company’s ability to continue as a going concern," Caesar's added.
06:27 EDTNVDATesla CEO calls autonomous cars 'solved,' says Tesla will be leader, WSJ says
Tesla (TSLA) CEO Elon Musk believes self-driving cars are "a solved problem... we know exactly what to do and we will be there in a few years," reports the Wall Street Journal, citing statements given at the Nvidia (NVDA) graphical processor conference Tuesday. Musk added that "I think [Tesla] will be the leader in autonomous cars that you can actually buy." The Journal notes that Nvidia will make its autonomous car development platform available in May to researchers and car makers. Reference Link
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use